EE344 Cost per Responder Associated with Bimekizumab Against Il-17A-Inhibitors in the Treatment of Axial Spondyloarthritis in Sweden
Dec 1, 2023, 00:00 AM
10.1016/j.jval.2023.09.610
https://www.valueinhealthjournal.com/article/S1098-3015(23)03740-3/fulltext
Section Title :
Section Order :
10099
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03740-3&doi=10.1016/j.jval.2023.09.610